ATE356200T1 - Kcnq kaliumkanäle und verfahren zur deren modulierung - Google Patents

Kcnq kaliumkanäle und verfahren zur deren modulierung

Info

Publication number: ATE356200T1
Authority: AT; Austria
Prior art keywords: kcnq2; proteins; kcnq3; potassium channels; disease
Prior art date: 1997-08-12

Application number

AT98932877T

Other languages

English (en)

Inventor

Michael A Blanar

Steven Dworetzky

Wen-Pin Yang

Paul C Levesque

Valentin K Gribkoff

Michael G Neubauer

Wayne A Little

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-12

Filing date

1998-06-26

Publication date

2007-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21998937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE356200(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-06-26 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE356200T1 publication Critical patent/ATE356200T1/de

Links

102000012359 KCNQ Potassium Channels Human genes 0.000 title 1
108010022282 KCNQ Potassium Channels Proteins 0.000 title 1
102000005453 KCNQ2 Potassium Channel Human genes 0.000 abstract 3
108010006746 KCNQ2 Potassium Channel Proteins 0.000 abstract 3
102000015686 KCNQ3 Potassium Channel Human genes 0.000 abstract 2
108010038888 KCNQ3 Potassium Channel Proteins 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000000044 Amnesia Diseases 0.000 abstract 1
206010003591 Ataxia Diseases 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
101000994667 Homo sapiens Potassium voltage-gated channel subfamily KQT member 2 Proteins 0.000 abstract 1
101000994663 Homo sapiens Potassium voltage-gated channel subfamily KQT member 3 Proteins 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
241001529936 Murinae Species 0.000 abstract 1
206010028632 Myokymia Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
102000004257 Potassium Channel Human genes 0.000 abstract 1
101100397814 Rattus norvegicus Kcnq2 gene Proteins 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
208000032257 benign familial neonatal 1 seizures Diseases 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
102000053004 human KCNQ2 Human genes 0.000 abstract 1
102000053006 human KCNQ3 Human genes 0.000 abstract 1
230000006984 memory degeneration Effects 0.000 abstract 1
208000023060 memory loss Diseases 0.000 abstract 1
208000005264 motor neuron disease Diseases 0.000 abstract 1
210000000653 nervous system Anatomy 0.000 abstract 1
230000004112 neuroprotection Effects 0.000 abstract 1
108020001213 potassium channel Proteins 0.000 abstract 1
230000005062 synaptic transmission Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT98932877T 1997-08-12 1998-06-26 Kcnq kaliumkanäle und verfahren zur deren modulierung ATE356200T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5559997P	1997-08-12	1997-08-12

Publications (1)

Publication Number	Publication Date
ATE356200T1 true ATE356200T1 (de)	2007-03-15

Family

ID=21998937

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98932877T ATE356200T1 (de)	1997-08-12	1998-06-26	Kcnq kaliumkanäle und verfahren zur deren modulierung

Country Status (10)

Country	Link
US (4)	US6403360B1 (de)
EP (1)	EP1007638B1 (de)
JP (1)	JP2001512673A (de)
AT (1)	ATE356200T1 (de)
AU (1)	AU731087B2 (de)
CA (1)	CA2300985A1 (de)
DE (1)	DE69837267T2 (de)
DK (1)	DK1007638T3 (de)
ES (1)	ES2281129T3 (de)
WO (1)	WO1999007832A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999007832A1 (en) *	1997-08-12	1999-02-18	Bristol-Myers Squibb Company	Kcnq potassium channels and methods of modulating same
EP1037900A4 (de) *	1997-10-24	2006-08-30	Univ Utah Res Found	Kcnq2 und kcnq3-kaliumkanalgene welche als mutanten bei gutartigen krämpfen bei neugeborenen und anderen formen von epilepsie vorliegen
ATE346152T1 (de) *	1999-04-14	2006-12-15	Merck & Co Inc	Neuartige menschliche kalium-potentialabhängige kanäle
JP4833467B2 (ja) *	1999-06-11	2011-12-07	ニューロサーチ、アクティーゼルスカブ	新規カリウムチャネル及び同カリウムチャネルをコードする遺伝子
US6649371B1 (en)	1999-06-11	2003-11-18	Neurosearch A/S	Potassium channel KCNQ5 and sequences encoding the same
US6472165B1 (en) *	1999-08-03	2002-10-29	Arzneimittelwerk Dresden Gmbh	Modulatory binding site in potassium channels for screening and finding new active ingredients
EP1200086A4 (de)	1999-08-04	2009-05-27	Icagen Inc	Methoden zur behandlung oder vorbeugung von schmerzen und angstzuständen
DE10013732A1 (de) *	2000-03-21	2001-09-27	Aventis Pharma Gmbh	Das Kaliumkanalprotein KCNQ5, ein neuer Angriffspunkt bei Erkrankungen des zentralen Nervensystems und des Herz-Kreislauf-Systems
US6617131B2 (en)	2000-03-21	2003-09-09	Aventis Pharma Deutschland Gmbh	Nucleic acid molecule encoding the potassium channel protein, KCNQ5
US7049137B2 (en) *	2000-03-21	2006-05-23	Icagen, Inc.	KCNQ5, a novel potassium channel
CA2404896A1 (en) *	2000-04-03	2001-10-11	Lexicon Genetics Incorporated	Human ion channel protein and polynucleotides encoding the same
WO2001092526A1 (en) *	2000-05-26	2001-12-06	Bristol-Myers Squibb Company	Human kcnq5 potassium channel, methods and compositions thereof
US6348486B1 (en) *	2000-10-17	2002-02-19	American Home Products Corporation	Methods for modulating bladder function
CA2438868A1 (en)	2001-02-20	2002-09-19	Valentin K. Gribkoff	Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
RU2607033C2 (ru) *	2010-09-28	2017-01-10	Ноно Инк.	Пептиды nd2 и способы лечения неврологического заболевания
FR3029113A1 (fr) *	2014-12-02	2016-06-03	Univ Paris-Sud	Composes pour le traitement des maladies mitochondriales
WO2021178769A1 (en) *	2020-03-06	2021-09-10	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating kcnq2
WO2025198930A1 (en) *	2024-03-18	2025-09-25	Humanwell Pharmacuetical Us, Inc.	Small molecules as kcnq2/3 (kv7.2/3) channel activators and their medical use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09191882A (ja)	1996-01-16	1997-07-29	Japan Tobacco Inc	ヒト新規ｋ＋チャネル蛋白質をコードするｄｎａおよびその断片
WO1999007832A1 (en) *	1997-08-12	1999-02-18	Bristol-Myers Squibb Company	Kcnq potassium channels and methods of modulating same
EP1037900A4 (de) *	1997-10-24	2006-08-30	Univ Utah Res Found	Kcnq2 und kcnq3-kaliumkanalgene welche als mutanten bei gutartigen krämpfen bei neugeborenen und anderen formen von epilepsie vorliegen

1998
- 1998-06-26 WO PCT/US1998/013276 patent/WO1999007832A1/en not_active Ceased
- 1998-06-26 US US09/105,058 patent/US6403360B1/en not_active Expired - Lifetime
- 1998-06-26 CA CA002300985A patent/CA2300985A1/en not_active Abandoned
- 1998-06-26 EP EP98932877A patent/EP1007638B1/de not_active Revoked
- 1998-06-26 JP JP2000506317A patent/JP2001512673A/ja active Pending
- 1998-06-26 ES ES98932877T patent/ES2281129T3/es not_active Expired - Lifetime
- 1998-06-26 AU AU82665/98A patent/AU731087B2/en not_active Ceased
- 1998-06-26 DE DE69837267T patent/DE69837267T2/de not_active Revoked
- 1998-06-26 DK DK98932877T patent/DK1007638T3/da active
- 1998-06-26 AT AT98932877T patent/ATE356200T1/de active
2002
- 2002-04-24 US US10/128,870 patent/US7041496B2/en not_active Expired - Lifetime
- 2002-04-24 US US10/131,685 patent/US7262289B2/en not_active Expired - Fee Related
2007
- 2007-02-16 US US11/707,363 patent/US7482431B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20030044912A1 (en)	2003-03-06
DK1007638T3 (da)	2007-05-21
US7041496B2 (en)	2006-05-09
AU8266598A (en)	1999-03-01
DE69837267D1 (de)	2007-04-19
ES2281129T3 (es)	2007-09-16
US6403360B1 (en)	2002-06-11
AU731087B2 (en)	2001-03-22
EP1007638A4 (de)	2004-12-29
US7482431B2 (en)	2009-01-27
EP1007638B1 (de)	2007-03-07
DE69837267T2 (de)	2007-10-31
CA2300985A1 (en)	1999-02-18
JP2001512673A (ja)	2001-08-28
WO1999007832A1 (en)	1999-02-18
US20070148692A1 (en)	2007-06-28
EP1007638A1 (de)	2000-06-14
US7262289B2 (en)	2007-08-28
US20020168724A1 (en)	2002-11-14

Similar Documents

Publication	Publication Date	Title
ATE356200T1 (de)	2007-03-15	Kcnq kaliumkanäle und verfahren zur deren modulierung
DE69841653D1 (de)	2010-06-17	Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
DE59807213D1 (de)	2003-03-20	11beta-halogen-7alpha-substituierte-estratriene, verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha-substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
BR9500052A (pt)	1995-10-03	Mutante de gênero escherichia e processo para produção de ácido L-glutâmico por fermentação
MXPA02001911A (es)	2003-07-21	Anticuerpos ctla-4 humanos y sus usos.
DE69637256D1 (de)	2007-10-31	Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
ATE397868T1 (de)	2008-07-15	Verfahren zur verbesserung der haut und des pelzes von haustieren
EA200200293A1 (ru)	2002-10-31	Бициклические аминокислоты в качестве фармацевтических агентов
DE69839801D1 (de)	2008-09-11	Intraokularlinsen und verfahren zur herstellung von eingesgossenen intraokularlinsen
WO2004058704A8 (en)	2005-10-27	Quinazolinones as potassium channel modulators
ATE552891T1 (de)	2012-04-15	Kombination von sauren-proteaseenzymen und sauren pufferlösungen sowie deren verwendung
EP1427377A4 (de)	2006-04-12	Verfahren und zusammensetzungen zur behandlung oder prävention von hauterkrankungen unter verwendung von bindemitteln, die für das prostataspezifische membranantigen spezifisch sind
ATE253128T1 (de)	2003-11-15	Katalytische nukleinsäuren und deren medizinische verwendung
ATE299179T1 (de)	2005-07-15	Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung
ATE259652T1 (de)	2004-03-15	Neuronale verwendungen des bmp-11
MX209576B (es)	2002-08-08	Proceso para la hidrogenacion continua de adiponitrilo
ATE221763T1 (de)	2002-08-15	Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
ATE391779T1 (de)	2008-04-15	Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal
BR9607745A (pt)	1998-06-23	Processo para produzir ácido 5-inosínico ou ácido 5' guanílico transformante dna recombinante proteina e gene
WO2001031008A3 (en)	2002-03-07	Human and rat fgf-20 genes and gene expression products
EA200001246A1 (ru)	2001-08-27	Карбамиды и карбаматы n-гетероциклических карбоновых кислот и изостер карбоновых кислот
ATE291095T1 (de)	2005-04-15	Enzymatisches verfahren zur stereoselektiven herstellung von therapeutischen amiden
ATE232721T1 (de)	2003-03-15	Verfahren zur vermehrung der produktion und zur verbesserung der qualität von sperma
DE69519799D1 (de)	2001-02-08	Verfahren zur herstellung von [s,s]-ethylendiamin-n,n'-dibernsteinsäure
DE59606567D1 (de)	2001-04-19	Neuer Mikroorganismus, dessen Verwendung und Verfahren zur Herstellung von L-Alpha-Aminosäuren

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1007638

Country of ref document: EP